Pharmacotherapies, which were not appropriately addressed in this particular study, have the ability to increase the likelihood of remission and/or recovery of anxiety symptoms. The use of pharmacological intervention should not be automatically withheld, despite the lack of studies that have been conducted in children.
When it comes to providing treatment for any type of mental disorder in a child, it is important for practitioners and clinicians to get into the habit of assessing whether they may be in violation of any ethical standards or principles. It is also important to consult with an expert or drug information specialist when it comes to initiating psychotropic medication in a young patient.
If it is determined that a patient would most likely benefit from therapy, he or she should then be monitored. By following an ethical decision-making process in clinical psychopharmacological treatment, primary care providers not only help to increase the chances of providing optimal and effective treatment to the patient, but they also protect themselves from possible liability that can arise as a result of not doing what is in the best interest of the patient after conducting a thorough assessment and evaluation process.
The goal is to deliver effective and appropriate patient care, and this can be done by weighing the risks and benefits of initiating therapy in each patient.
The overall selection of medication therapy is a continuous process that requires due diligence and attention to detail to make a final decision about therapy. This is a collaborative decision that should exist between the patient and the provider.
Abimbola Farinde, PhD, PharmD, is a professor at Columbia Southern University in Orange Beach, Ala.